Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B-14 and B-20 Trials

Documenti analoghi

• Comparison of the Prognostic and Predictive Utilities of the 21-Gene Recurrence Score Assay and Adjuvant! for Women with Node-Negative, ER-Positive Breast Cancer: Results from NSABP B-14 and NSABP B-20
  di: Tang, Gong, et al.
  Pubblicazione: (2011)
• Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
  di: Mamounas, Eleftherios P., et al.
  Pubblicazione: (2010)
• Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial
  di: Pusztai, Lajos, et al.
  Pubblicazione: (2009)
• A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology/NSABP B-42
  di: Mamounas, Eleftherios P., et al.
  Pubblicazione: (2018)
• Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
  di: Pogue-Geile, Katherine L., et al.
  Pubblicazione: (2015)